Rituxan (rituximab) / Zenyaku Holdings, Biogen, Roche  >>  Phase 2
Welcome,         Profile    Billing    Logout  

545 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rituxan (rituximab) / Roche
waveLINE-007, NCT05406401 / 2021-005861-41: A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)

Recruiting
2
60
Europe, Canada, RoW
Zilovertamab Vedotin, MK-2140, VLS-101, Cyclophosphamide, CYTOXAN®, NEOSAR®, Doxorubicin, ADRIAMYCIN®, Rituximab, RITUXAN®, Rituximab Biosimilar, TRUXIMA®, Prednisone, Prednisolone
Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Lymphoma, Large B-Cell, Diffuse (DLBCL)
01/26
01/26
NCT05600686: Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma

Recruiting
2
24
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16, Loncastuximab Tesirine, ADC ADCT-402, ADCT-402, Anti-CD19 PBD-conjugate ADCT-402, Loncastuximab Tesirine-lpyl, Zynlonta, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Riabni, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, rituximab-abbs, Rituximab-arrx, Rituximab-pvvr, RTXM83, Ruxience, Truxima, Vincristine, Leurocristine, VCR, Vincrystine
Joseph Tuscano, National Cancer Institute (NCI), ADC Therapeutics S.A.
Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
02/26
02/28
NCT05736419: A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

Recruiting
2
24
US
Fludarabine, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, Rabbit ATG, Dexamethasone, Bortezomib, Rituximab
Memorial Sloan Kettering Cancer Center
Sickle Cell Disease, Thalassemia, Beta, Thalassemia
02/26
02/26
SAKK 38/19, NCT04604067: Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial.

Recruiting
2
260
Europe
Acalabrutinib
Swiss Group for Clinical Cancer Research
Diffuse Large B-cell Lymphoma
10/25
12/30
NCT04684979: Transplantation of Hematopoietic Stem Cells From HLA-compatible Donors in Patients With B-Cell Lymphoid Malignancies

Withdrawn
2
90
US
Hematopoietic Stem Cells from HLA-compatible Related, Hematopoietic Stem Cells from HLA Unrelated
Baptist Health South Florida
B-Cell Lymphoid Malignancies, Hematologic Malignancy, Non-Hodgkin Lymphoma
03/26
03/27
NCT05929716: An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma

Withdrawn
2
28
NA
Magrolimab, Rituximab, CAR T leukapheresis, Radiation
M.D. Anderson Cancer Center
Large B-cell Lymphoma, B-cell Lymphoma
03/26
03/28
Ra-P-OCD, NCT04323566: Rituximab Treatment for Psychosis and/or Obsessive Compulsive Disorder With Probable Immune System Involvement

Enrolling by invitation
2
40
Europe
Rituximab
Uppsala University Hospital, Uppsala University
Obsessive-Compulsive Disorder, Obsessive-Compulsive Behavior, Schizophrenia, Delusional Disorder, Brief Psychotic Disorder, Schizo Affective Disorder, Other Psychoses, Unspecified Psychosis
04/26
05/26
NCT05926427: Orelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Nervous System Involvement

Recruiting
2
25
RoW
Orelabrutinib, ICP-022, Rituximab, Chemotherapy
Ruijin Hospital
CNS Lymphoma
04/26
04/26
MTR², NCT05583071: Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL

Not yet recruiting
2
20
Europe
Tafasitamab, Lenalidomide, Rituximab, Methotrexate
University of Cologne, Incyte Corporation
Non-Hodgkin Lymphoma
02/27
04/27
NCT05874778: A Multicenter, Phase 2 Study Evaluating the Value of Radiotherapy in Advanced Diffuse Large B-cell Lymphoma Patients With Extranodal Involvement and Large Tumors Undergoing Immunochemotherapy for PET-CT Assessment of Complete Remission

Not yet recruiting
2
108
NA
6-8 cycles (21 days per cycle) of Standard R-CHOP chemotherapy, Radiotherapy beyond standard R-CHOP Chemotherapy
Tianjin Medical University Cancer Institute and Hospital
Advanced Diffuse Large B-Cell Lymphoma, Extra-nodal Involvement, Large Mass, Radiotherapy
05/26
05/26
Ballondor, NCT03697356: R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's Macroglobulinemia

Recruiting
2
54
RoW
Lenalidomide, Bortezomib, Rituximab, Dexamethasone
Kosin University Gospel Hospital
Waldenström's Macroglobulinemia
05/26
06/26
CARAMEL, NCT05004064: Acalabrutinib and Rituximab in Previously Untreated Mantle Cell Lymphoma

Not yet recruiting
2
26
NA
Acalabrutinib, Rituximab
University College, London, AstraZeneca
Mantle Cell Lymphoma
05/26
05/26
NCT05864742: Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma

Recruiting
2
40
RoW
Ibrutinib, imbruvica, Venetoclax, Venclexta, Navitoclax, ABT-263, Rituximab, Rituxan
Peter MacCallum Cancer Centre, Australia
Mantle Cell Lymphoma Refractory
06/26
06/29
RCT-RITS2022, NCT05622201: A Randomized Controlled Trial With Rituximab for Psychotic Disorder in Adults

Recruiting
2
120
Europe
Rituximab, Saline
Region Örebro County
Schizophrenia Spectrum and Other Psychotic Disorders
06/26
12/26
NCT05843968: Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Nephrotic Syndrome

Recruiting
2
46
RoW
Rituximab, Rituximab Injection, Mycophenolate Mofetil, Mycophenolate Mofetil Dispersible tablets
Children's Hospital of Chongqing Medical University
Nephrotic Syndrome in Children
07/26
07/26
BeliVeR, NCT05069051: Belimumab in Patients With Chronic Lymphocytic Leukemia

Recruiting
2
120
Europe
Belimumab 200 MG/ML [Benlysta], standard of care
University Hospital Tuebingen, GlaxoSmithKline
Chronic Lymphoid Leukemia in Relapse
07/26
07/27
NCT04765111: Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma

Active, not recruiting
2
53
US
Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Calquence, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima
M.D. Anderson Cancer Center
Mantle Cell Lymphoma
08/26
08/26
CLSGMCLPOLA, NCT04913103: Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL

Not yet recruiting
2
21
RoW
Polatuzumab vedotin, Polivy, Bendamustine Hydrochloride, Bendamustine Accord, Bendamustine Glenmark, Bendamustine KABI, Rituximab, Mabthera, Rixathon, Truxima
Czech Lymphoma Study Group
Lymphoma, Mantle-Cell
08/26
08/27
SATELITE, NCT04871191: Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis

Not yet recruiting
2
42
Europe
Rituximab, Mabthera, Tocilizumab, RoActemra, Abatacept, Orencia
Assistance Publique - Hôpitaux de Paris, URC-CIC Paris Descartes Necker Cochin
Granulomatosis With Polyangiitis, Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
09/26
01/27
NCT05800366: A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

Recruiting
2
40
US
Glofitamab, RO7082859, Polatuzumab, Polatuzumab vedotin, DCDS4501S, RG7596, Rituximab, Rituxan, Doxorubicin Hydrochloride, Hydroxydaunomycin, Cyclophosphamide, Cytophosphane, Cytoxan, Prednisone, Prednisolone, Methylprednisolone
Jennifer Crombie, MD, Genentech, Inc.
Lymphoma, Lymphoma, Large B-Cell, Diffuse
09/26
09/29
RITA-MI2, NCT05211401: Rituximab in Patients With ST-elevation Myocardial Infarction

Recruiting
2
558
Europe
Active arm 200 mg, Active arm 1000 mg, Placebo arm
Assistance Publique - Hôpitaux de Paris, Institut National de la Santé Et de la Recherche Médicale, France
ST Elevated Myocardial Infarction
10/26
04/27
VIWA-1, NCT05099471: Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia

Not yet recruiting
2
80
NA
Venetoclax; Rituximab, Venetoclax / Rituximab, DRC, Dexamethasone / Rituximab / Cyclophosphamide
University of Ulm, Ludwig-Maximilians - University of Munich, Zentrum für Klinische Studien Ulm, AbbVie, Pfizer, University Hospital Schleswig-Holstein, Campus Kiel
Waldenstrom Macroglobulinemia
10/27
10/32
NCI-2017-00596, NCT02877303: Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia

Recruiting
2
80
US
Blinatumomab, Anti-CD19 x Anti-CD3 Bispecific Monoclonal Antibody, Anti-CD19/Anti-CD3 Recombinant Bispecific Monoclonal Antibody MT103, Blincyto, MEDI-538, MT-103, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Inotuzumab Ozogamicin, Besponsa, CMC-544, Way 207294, WAY-207294, Laboratory Biomarker Analysis, Mercaptopurine, 3H-Purine-6-thiol, 6 MP, 6 Thiohypoxanthine, 6 Thiopurine, 6-Mercaptopurine, 6-Mercaptopurine Monohydrate, 6-MP, 6-Purinethiol, 6-Thiopurine, 6-Thioxopurine, 6H-Purine-6-thione, 1,7-dihydro- (9CI), 7-Mercapto-1,3,4,6-tetrazaindene, Alti-Mercaptopurine, Azathiopurine, Bw 57-323H, Flocofil, Ismipur, Leukerin, Leupurin, Mercaleukim, Mercaleukin, Mercaptina, Mercaptopurinum, Mercapurin, Mern, NCI-C04886, Puri-Nethol, Purimethol, Purine, 6-mercapto-, Purine-6-thiol (8CI), Purine-6-thiol, monohydrate, Purinethiol, Purinethol, U-4748, WR-2785, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Ofatumumab, Arzerra, GSK1841157, HuMax-CD20, HuMax-CD20, 2F2, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma
11/26
11/26
NCT05065554: ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy

Recruiting
2
33
US
Acalabrutinib, Calquence, Rituximab, Rituxan
Shayna Sarosiek, MD, AstraZeneca
IgM MGUS, Waldenstrom Macroglobulinemia, Neuropathy;Peripheral
12/26
10/28
NCI-2019-08358, NCT04216524: Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

Recruiting
2
40
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Mercaptopurine, 3H-Purine-6-thiol, 6 MP, 6 Thiohypoxanthine, 6 Thiopurine, 6-Mercaptopurine, 6-Mercaptopurine Monohydrate, 6-MP, 6-Purinethiol, 6-Thiopurine, 6-Thioxopurine, 6H-Purine-6-thione, 1,7-dihydro- (9CI), 7-Mercapto-1,3,4,6-tetrazaindene, Alti-Mercaptopurine, Azathiopurine, Bw 57-323H, Flocofil, Ismipur, Leukerin, Leupurin, Mercaleukim, Mercaleukin, Mercaptina, Mercaptopurinum, Mercapurin, Mern, NCI-C04886, Puri-Nethol, Purimethol, Purine, 6-mercapto-, Purine-6-thiol (8CI), Purine-6-thiol, monohydrate, Purinethiol, Purinethol, U-4748, WR-2785, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Methylprednisolone, Adlone, Caberdelta M, DepMedalone, Depo Moderin, Depo-Nisolone, Duralone, Emmetipi, Esametone, Firmacort, Medlone 21, Medrate, Medrol, Medrol Veriderm, Medrone, Mega-Star, Meprolone, Methylprednisolonum, Metilbetasone Solubile, Metrocort, Metypresol, Metysolon, Predni-M-Tablinen, Prednilen, Radilem, Sieropresol, Solpredone, Summicort, Urbason, Veriderm Medrol, Wyacort, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima, Tagraxofusp-erzs, Diphtheria Toxin(388)-Interleukin-3 Fusion Protein, DT(388)-IL3 Fusion Protein, DT388IL3 fusion protein, Elzonris, IL3R-targeting Fusion Protein SL-401, SL-401, Tagraxofusp, Tagraxofusp ERZS, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto, Vincristine, Leurocristine, VCR, Vincrystine
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Blastic Plasmacytoid Dendritic Cell Neoplasm
12/26
12/26
NCT06046248: Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease

Recruiting
2
25
US
Belumosudil, Rituximab
Northside Hospital, Inc., Sanofi
Chronic Graft Versus Host Disease
12/26
12/27
NCT03789240: Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma

Active, not recruiting
2
22
US
Rituximab, Copanlisib
National Cancer Institute (NCI)
Follicular Lymphoma, Non-Hodgkin's Lymphoma, NHL
01/27
01/27
ALTAMIRA, NCT05214183: Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma

Active, not recruiting
2
81
Europe, RoW
Acalabrutinib-rituximab in patients with untreated mantle cell lymphoma
Nordic Lymphoma Group, AstraZeneca
MCL, Mantle Cell Lymphoma
01/27
01/27
TOP-FLOR, NCT05788081: Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab.

Recruiting
2
40
RoW
golcadomide, BMS-986369, CC-99282, Nivolumab 10 MG/ML, Opdivo, Rituximab, Mabthera
Olivia Newton-John Cancer Research Institute, Austin Health, Grampians Health, Fiona Stanley Hospital, Eastern Health, Barwon Health, Bristol-Myers Squibb
Follicular Lymphoma Stage II, Follicular Lymphoma Stage III, Follicular Lymphoma Stage IV
01/27
06/27
NCT05868395: Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma

Recruiting
2
16
Europe
Polatuzumab, bendamustin und rituximab, Polivy, Bendamustin, Mabthera
Medical University of Vienna
Mantle-cell Lymphoma
05/27
05/27
ACRUE, NCT05952024: Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL

Not yet recruiting
2
80
NA
Acalabrutinib, CALQUENCE®, Rituximab
AstraZeneca
Diffuse Large B-Cell Lymphoma
09/27
09/27
NCT04480450: Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy

Not yet recruiting
2
40
NA
Rituximab
University of Kansas Medical Center
Chronic Inflammatory Demyelinating Polyneuropathy
08/27
08/27
R-Pola-Glo, NCT05798156: Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP

Recruiting
2
80
Europe
Glofitamab, Rituximab, Obinutuzumab, Polatuzumab vedotin
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Charite University, Berlin, Germany, University of Salzburg, Arbeitsgemeinschaft medikamentoese Tumortherapie, Roche Pharma AG, Zentrum für Klinische Studien Leipzig, Hoffmann-La Roche
Lymphoma, Large B-Cell, Diffuse
09/27
09/28
NCT03929601: Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes

Recruiting
2
74
US, RoW
Rituximab-pvvr, Ruxience, Abatacept, Orencia, Sterile Sodium Chloride, 0.9% Sodium Chloride Water for Injection
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH)
Type 1 Diabetes Mellitus
10/27
10/29
NCT05735717: MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Recruiting
2
150
US
Fludarabine, Busulfan, Melphalan, Rituximab, Levetiracetam, Keppra
Masonic Cancer Center, University of Minnesota
Hematologic Malignancy, Acute Leukemia, Remission, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, AML, TP53, Intrachromosomal Amplification of Chromosome 21, Cytogenetic Abnormality, CNS Leukemia, Minimal Residual Disease, Myelodysplasia, Juvenile Myelomonocytic Leukemia, Somatic Mutation, PTPN11 Gene Mutation, N-RAS Gene Amplification, Neurofibromatosis 1, NF1 Mutation, CBL Gene Mutation, Monosomy 7, Chromosome Abnormality, Fetal Hemoglobin
11/27
11/30
cRIB, NCT05645718: Study of Pedi- Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab () for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

Recruiting
2
27
US
Cyclophosphamide, Cytoxan®, Neosar®, Vincristine, Blinatumomab, Methotrexate, Cytarabine, Ara-C, Cytosar®, DepoCyt™, Cytosine arabinosine hydrochloride, Mercaptopurine, 6-mercaptopurine, Purinethol®, 6-MP, Prednisone, Pegfilgrastim, NeulastaTM, PEG-G-CSF, Inotuzumab ozogamicin, CMC-544, Rituximab, Rituxan, Dexamethasone, Decadron
M.D. Anderson Cancer Center
Leukemia
12/27
12/29
NCT05303792: Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma

Recruiting
2
66
US
Cyclophosphamide, Vincristine, Dexamethasone, Inotuzumab Ozogamicin, Methotrexate, Cytarabine, Methylprednisolone, Rituximab, Prednisone, Mercaptopurine, Doxorubicin
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma
05/25
05/28
NCT05998642: Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma

Recruiting
2
30
Canada
Methotrexate, Rituximab (where available), Ibrutinib
Canadian Cancer Trials Group, Janssen Inc.
Non-hodgkin Lymphoma
05/28
12/28
NCT06045247: Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

Recruiting
2
40
US
Prednisone, Rituximab, Cyclophosphamide, Vincristine, Epcoritamab
M.D. Anderson Cancer Center
Large B-cell Lymphoma
07/28
07/30
ZEBRA, NCT05635162: Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma

Recruiting
2
50
Europe
Zanubrutinib, Rituximab
University College, London, BeiGene
Mantle Cell Lymphoma
10/28
10/28
KICS, NCT01419561: Natural History Study of the KSHV Inflammatory Cytokine Syndrome

Recruiting
2
140
US
Zidovudine, Liposomal Doxorubicin, Valganiclovir, Rituximab, Standard Therapies, Cohort 1
National Cancer Institute (NCI)
KSHV Inflammatory Cytokine Syndrome (KICS), KSHV, HHV-8
12/28
12/28
TrAVeRse, NCT05951959: A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma

Hourglass Dec 2023 - Dec 2023 : Data from TrAVeRse trial in patients with treatment- naïve mantle cell lymphoma at ASH 2023
Hourglass Jan 2020 - Dec 2020 : From ACE-CL-208 trial in r/r CLL
Recruiting
2
100
Europe, Canada, US, RoW
Acalabrutinib, Acalabrutinib, CALQUENCE, Venetoclax, Rituximab
AstraZeneca
Mantle Cell Lymphoma (MCL)
01/29
01/29
EPCORE NHL-5, NCT05283720 / 2021-005725-24: A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Recruiting
2
394
Europe, Japan, US, RoW
Epcoritamab, ABBV-GMAB-3013;, Lenalidomide, Ibrutinib, Imbruvica, Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride [HCl], Prednisone, Polatuzumab Vedotin, Venetoclax, Venclexta;, ABT-199, GDC-0199, CC-99282
Genmab, AbbVie
Non-Hodgkin Lymphoma
11/32
11/32
REFRACT, NCT05848765: Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy

Recruiting
2
284
Europe
Epcoritamab, Lenalidomide, Rituximab, Obinutuzumab, Bendamustine, Vincristine, Doxorubicin, Cyclophosphamide, Prednisone, Investigation agent 2, Investigation agent 3
University of Birmingham, Cancer Research UK, Genmab
Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma
05/29
11/31
NCT05245656: A Study Comparing Rituximab/Bendamustin(RB) Alternating With Rituximab/Bendamustin/Cytarabin(RBAC) With RB Therapy in Elderly Patients With Mentle Cell Lymphoma

Recruiting
2
90
RoW
RB/RBAC alternating, RB
Kim, Seok Jin
Mantle Cell Lymphoma
12/29
12/29
NCT00001379: Treatment and Natural History Study of Lymphomatoid Granulomatosis

Active, not recruiting
2
93
US
Interferon, Rituxan and EPOCH
National Cancer Institute (NCI)
Lymphomatoid Granulomatosis, Granulomatosis, Lymphomatoid, Non-Hodgkins Lymphoma, Lymphoproliferative Disorder
02/30
02/34
NCT04114136: Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

Recruiting
2
72
US
Nivolumab or Pembrolizumab (dependent upon approved indication), Opdivo (nivolumab) or Keytruda (pembrolizumab), Metformin, Glucophage, Glucophage XR, Fortamet, and Glumetza, Rosiglitazone, Avandia
Dan Zandberg
Melanoma, NSCLC, Hepatocellular Carcinoma, Urothelial Cancer, Gastric Adenocarcinoma, HNSCC, Esophageal Adenocarcinoma, Microsatellite Instability-High Solid Malignant Tumor
04/32
04/32
NCT05508009: Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor

Recruiting
1b/2a
12
US
Cyclophosphamide 1200 mg/Kg, Fludarabine, Cyclophosphamide 100 mg/Kg, Total Body Irradiation, TBI, ATG, Rituximab, Melphalan, CliniMACS® TCR α/β Reagent Kit and CliniMACS® CD19 System, Kidney Transplant
Alice Bertaina, California Institute for Regenerative Medicine (CIRM)
SIOD, Cystinosis, FSGS, SLE Nephritis, CKD Stage 4
10/32
10/34
NCT02158091: A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL

Active, not recruiting
1b/2
32
US
IPI-145, Fludarabine, Fludara, Cyclophosphamide, Cytoxan®, Neosar®, Rituximab, Rituxan
Dana-Farber Cancer Institute, Secura Bio, Inc.
Chronic Lymphocytic Leukemia
10/17
07/25
ACTRN12612000746831: A Phase I/II trial to determine the Safety, Toxicity and Efficacy of Iodine-131-Rituximab and the Histone Deacetylase Inhibitor Panobinostat in Relapsed and Refractory Indolent B-cell Lymphoma

Recruiting
1/2
30
 
Peter MacCallum Cancer Centre, Peter MacCallum Cancer Centre, Novartis Pharmaceuticals Australia Pty Limited
Relapsed and Refractory Indolent B-cell Lymphoma
 
 
ACTRN12608000627358: APO2L/TRAIL in Combination With Rituximab in Subjects Non-Hodgkin's Lymphoma

Recruiting
1/2
105
 
Genentech, Genentech, Genentech
Non-Hodgkin's Lymphoma
 
 
BVX20a: A clinical trial on an anticancer agent in patients with Non Hodgkin's Lymphoma

Recruiting
1/2
50
India
BVX-20 (rituximab biosimilar)
Biocon
NHL
 
 
NCT01297478: Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, Prednisone, Rituximab, Pegfilgrastim, and Sargramostim as Front-Line Therapy in Treating Patients With Aggressive Non-Hodgkin Lymphoma

Recruiting
1/2
60
US
pegfilgrastim, rituximab, sargramostim, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, R-CHOP regimen, external beam radiation therapy
Auxilio Mutuo Cancer Center
Lymphoma
04/11
 
2011-005474-38: The use of isotope-bound antibodies to visualize and subsequently treat B-cell lymphoma

Ongoing
1/2
20
Europe
89Zr-N-sucDf-rituximab, 90Y-DOTA-rituximab, none, Solution for infusion
Institut Jules Bordet, FNRS - Télévie, Les Amis de Bordet, National Cancer Plan
CD20 positive Lymphoma, patients with a lymphoma of B cells that expresses CD20, Diseases [C] - Cancer [C04]
 
 
2011-000097-56: A randomised phase I/II trial of lenalidomide and rituximab with or withoutbendamustine in patients ≥ 18 years with relapsed follicular lymphoma

Ongoing
1/2
168
Europe, RoW
Lenalidomide (Revlimid 5 mg), Lenalidomide (Revlimid 10 mg), Lenalidomide (Revlimid 15 mg), Rituximab, Bendamustine hydrochloride 25mg (Levact), Bendamustine hydrochloride 100mg (Levact), EU/1/07/391/001, Capsule, hard, Concentrate and solvent for solution for infusion, Powder for concentrate for solution for infusion, Powder and solvent for concentrate for solution for infusion, Revlimid 5 mg capsules, Revlimid 10 mg capsules, Revlimid 15 mg hard capsules, Mabthera, Levact
HOVON Foundation, KWF, Celgene, Mundipharma, Cancer Research UK grant (CTAAC), HOVON Foundation
Follicular lymphoma., Cancer in the lymph nodes., Diseases [C] - Cancer [C04]
 
 
NCI-2011-00344, NCT01318317: Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma

Active, not recruiting
1/2
8
US
Autologous Hematopoietic Stem Cell Transplantation, AHSCT, Autologous, Autologous Hematopoietic Cell Transplantation, Autologous Stem Cell Transplant, Autologous Stem Cell Transplantation, Stem Cell Transplantation, Autologous, Filgrastim, Filgrastim-aafi, G-CSF, Neupogen, Nivestym, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, rG-CSF, Tevagrastim, Genetically Engineered Lymphocyte Therapy, Laboratory Biomarker Analysis, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, PBSCT, Peripheral Blood Progenitor Cell Transplantation, PERIPHERAL BLOOD STEM CELL TRANSPLANT, Peripheral Stem Cell Support, Peripheral Stem Cell Transplant, Peripheral Stem Cell Transplantation, Plerixafor, AMD 3100, JM-3100, Mozobil, SDZ SID 791, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima
City of Hope Medical Center, National Cancer Institute (NCI)
Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma
10/13
12/24
2013-002711-94: HOVON 124 WM study: A trial of the combination of ixazomib citrate, rituximab and dexamethasone in patients with relapsed or progressive Waldenström's macroglobulinemia.

Ongoing
1/2
72
Europe
MLN9708 4 mg, rituximab, MLN9708 3 mg, MLN9708 2,3 mg, Capsule, hard, Concentrate for solution for infusion, Solution for injection, Mabthera 100mg/10ml, Mabthera 500mg/50ml, Mabthera s.c.
HOVON Foundation, Dutch Cancer Society, Millennium, Roche Nederland BV, Roche Belgium, Roche (Hellas) S.A.
Waldenström's macroglobulinemia, Morbus Waldenström, Diseases [C] - Cancer [C04]
 
 
NCT00972478: Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

Active, not recruiting
1/2
83
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B-518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, WR-138719, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Laboratory Biomarker Analysis, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Riabni, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-pvvr, RTXM83, Ruxience, Truxima, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate, Vorinostat, L-001079038, MSK-390, SAHA, Suberanilohydroxamic Acid, Suberoylanilide Hydroxamic Acid, Zolinza
National Cancer Institute (NCI)
Ann Arbor Stage II Non-Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma
12/15
03/25
2007-007698-22: A PHASE IB/II STUDY OF ESCALATING DOSES OF REVLIMID IN ASSOCIATION WITH R-CHOP (R2-CHOP) IN THE TREATMENT OF B-CELL LYMPHOMA

Ongoing
1/2
110
Europe
REVLIMID, REVLIMID
GELARC
B cell lymphoma
 
 
2008-007246-60: Lenalidomide, bendamustine and rituximab as first-line therapy for patients >65 years with mantle cell lymphoma

Ongoing
1/2
40
Europe
Revlimid, Revlimid, Mabthera, Ribomustin, Revlimid, Mabthera, Ribomustin
Nordic Lymphoma Group
Mantle cell lymphoma
 
 
NCT00863369: Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma

Completed
1/2
33
US
rituximab, IDEC-C2B8, IDEC-C2B8 monoclonal antibody, Mabthera, MOAB IDEC-C2B8, Rituxan, bortezomib, LDP 341, MLN341, VELCADE, gemcitabine hydrochloride, dFdC, difluorodeoxycytidine hydrochloride, gemcitabine, Gemzar, questionnaire administration
City of Hope Medical Center, National Cancer Institute (NCI)
Lymphoma
08/16
06/23
ChiCTR2000037732: Therapeutic Strategy and the Role of Mesenchymal Stromal Cells for ABO Incompatible Liver Transplantation

Completed
1/2
22
 
Umbilical cord-derived mesenchymal stem cells (UC-MSCs) ;Rituximab
The Third Affiliated Hospital of Sun Yat-Sen University; The Third Affiliated Hospital of Sun Yat-Sen University, Science and Technology Planning Project of Guangzhou city
severe hepatic failure
 
 
ACCEPT, NCT03571308 / 2015-003213-18: A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL)

Completed
1/2
39
Europe
R-CHOP + acalabrutinib, Rituximab, Cyclophosphamide, Vincristine, Doxorubicin, Prednisolone, Acalabrutinib
University Hospital Southampton NHS Foundation Trust
Non Hodgkin Lymphoma
01/20
08/23
2019-000111-84: A study of Acalabrutinib alone, or in combination with Rituximab and Lenalidomide for subjects with B-cell Non Hodgkin Lymphoma Studio di acalabrutinib da solo o in associazione con Rituximab e Lenalidomidein soggetti con linfoma non Hodgkin a cellule B

Not yet recruiting
1/2
120
Europe
Acalabrutinib, Rituximab, Revlimid®, Revlimid, [ACP-196], [Rituximab], [Revlimid®], [Revlimid], Capsule, hard, Concentrate for solution for infusion, MabThera, Revlimid®
ACERTA PHARMA BV, Acerta Pharma BV
B-cell Non-Hodgkin Lymphoma Linfoma Non-Hodgkin a cellule B, B-cell Non-Hodgkin Lymphoma Linfoma Non-Hodgkin a cellule B, Diseases [C] - Cancer [C04]
 
 
ZUMA-1, NCT02348216 / 2015-005007-86: Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

Checkmark Data from ZUMA-1 trial for R/R LBCL at ASH 2022
Dec 2022 - Dec 2022: Data from ZUMA-1 trial for R/R LBCL at ASH 2022
Checkmark Presentation from ZUMA-1 trial for DLBCL at ASTCT 2021
Feb 2021 - Feb 2021: Presentation from ZUMA-1 trial for DLBCL at ASTCT 2021
Checkmark Presentation from ZUMA-1 trial for DLBCL at ASH 2020
More
Completed
1/2
307
Europe, Canada, US, RoW
Axicabtagene Ciloleucel, Yescarta®, Fludarabine, Cyclophosphamide, Levetiracetam, Tocilizumab, Dexamethasone, High-dose methylprednisolone, Bendamustine, Rituximab, Doxorubicin, Prednisone, Vincristine, Ifosfamide, Carboplatin, Etoposide, Gemcitabine, Oxaliplatin, Cisplatin, Methylprednisolone
Kite, A Gilead Company
Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL), Primary Mediastinal B-cell Lymphoma (PMBCL), High Grade B-cell Lymphoma (HGBCL)
07/23
07/23
NCT02481310: Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma

Active, not recruiting
1/2
38
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosar-U, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16-213, VP-16, VP-16-213, Ixazomib Citrate, MLN-9708, MLN9708, Laboratory Biomarker Analysis, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisonum, Prednitone, Promifen, Servisone, SK-Prednisone, Rituximab, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab Biosimilar BI 695500, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, RTXM83, Therapeutic Hydrocortisone, Aeroseb-HC, Barseb HC, Barseb-HC, Cetacort, Cort-Dome, Cortef, Cortenema, Cortifan, Cortisol, Cortispray, Cortril, Dermacort, Domolene, Eldecort, Hautosone, Heb-Cort, HYDROCORTISONE, Hydrocortone, Hytone, Komed-HC, Nutracort, Proctocort, Rectoid, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
Northwestern University, National Cancer Institute (NCI), Millennium Pharmaceuticals, Inc.
Adult Burkitt Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, MYC Gene Mutation, Plasmablastic Lymphoma
09/20
07/24
2020-000354-10: A study to evaluate how safe is CC-220, how is the body affected by CC-220, and a preliminary idea on how CC-220 works, when given alone or together with a medicine to treat cancer, in patients with lymphoma that is not responding to treatment or that has re-appeared.

Not yet recruiting
1/2
232
Europe
Iberdomide, CC-220, Concentrate for concentrate for solution for infusion, Solution for injection, Capsule, hard, Mabthera, Gazyvaro
Celgene Corporation, Celgene Corporation
Relapsed or refractory lymphoma including the following subtypes:Aggressive B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma and classical Hodgkin lymphoma., Different forms of type of blood cancer, called lymphoma, that is not responding to treatment or that has re-appeared., Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT02073097: Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma

Completed
1/2
48
US
Carfilzomib, Kyprolis, PR-171, Rituximab, IDEC-C2B8, IDEC-C2B8 monoclonal antibody, Mabthera, MOAB IDEC-C2B8, Rituxan, Cyclophosphamide, CPM, CTX, Cytoxan, Endoxan, Endoxana, Doxorubicin hydrochloride, ADM, ADR, Adria, Adriamycin PFS, Adriamycin RDF, Vincristine sulfate, leurocristine sulfate, VCR, Vincasar PFS, Prednisone, DeCortin, Deltra, Pegfilgrastim, Neulasta, Recombinant methionyl human granulocyte colony-stimulating factor (G-CSF), Acyclovir, Zovirax
Case Comprehensive Cancer Center
Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma
07/21
06/23
MC078E, NCT00670358: Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Active, not recruiting
1/2
138
US
pegfilgrastim, rituximab, cyclophosphamide, doxorubicin hydrochloride, lenalidomide, prednisone, vincristine sulfate, polymorphism analysis, laboratory biomarker analysis
Mayo Clinic, National Cancer Institute (NCI)
Lymphoma
05/21
11/24
NCT02628405: R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma

Active, not recruiting
1/2
63
US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16, Ifosfamide, Asta Z 4942, Asta Z-4942, Cyfos, Holoxan, Holoxane, Ifex, IFO, IFO-Cell, Ifolem, Ifomida, Ifomide, Ifosfamidum, Ifoxan, IFX, Iphosphamid, Iphosphamide, Iso-Endoxan, Isoendoxan, Isophosphamide, Mitoxana, MJF 9325, MJF-9325, Naxamide, Seromida, Tronoxal, Z 4942, Z-4942, Laboratory Biomarker Analysis, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Riabni, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, rituximab-abbs, Rituximab-arrx, Rituximab-pvvr, RTXM83, Ruxience, Truxima
Academic and Community Cancer Research United, National Cancer Institute (NCI)
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma
09/21
12/25
2018-003235-29: An early study to investigate a new medicine for Subjects with Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

Not yet recruiting
1/2
348
Europe
CC-99282, Gazyvaro, Tafasitamab, Rituximab, valemetostat, CC-99282, Capsule, Concentrate for solution for infusion, Concentrate and solvent for solution for infusion, Tablet, MabThera 100 mg concentrate for solution for infusion, Gazyvaro, Monjuvi
Celgene Corporation, Celgene Corporation
Subjects with R/R NHL, which includes diffuse large B-cell lymphoma (DLBCL) (not otherwise specified [NOS] or transformed), FL (follicular lymphoma), mantle cell lymphoma (MCL), primary central nervous system lymphoma (PCNSL) or relapsed or refractory marginal zone lymphoma (MZL) who have failed at least 2 lines of therapy (or who have received at least one prior line of standard therapy and are not eligible for any other therapy)., Patients who have stopped responding or have failed to respond to treatment for cancer of a type of white blood cell., Diseases [C] - Cancer [C04]
 
 
NCT00293475: Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

Active, not recruiting
1/2
81
US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Mannitol, D-Mannitol, Mannitol, D-, Osmitrol, Resectisol, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Quality-of-Life Assessment, Quality of Life Assessment, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima, Sodium Thiosulfate, Cyanide Antidote Package, Disodium Thiosulfate, S-Hydril, Sodium Hyposulfate, Sodium Thiosulfate Pentahydrate, Sodium Thiosulphate, Sodothiol, Thiosulfate, Sodium, Pentahydrate, Thiosulfuric Acid Disodium Salt
OHSU Knight Cancer Institute, National Cancer Institute (NCI), Oregon Health and Science University
Central Nervous System Lymphoma
01/22
01/23
NCT02678299 / 2015-000758-39: Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study

Active, not recruiting
1/2
60
Europe
PREBEN
University of Aarhus
Malignant Lymphoma
02/22
12/25
REMLA, NCT04120350: R2-MTX With Lenalidomide Maintenance in Newly-diagnosed PCNSL：a Multicenter Phase Ib/II Stuty

Recruiting
1/2
47
RoW
Methotrexate, Rituximab, Lenalidomide
Peking Union Medical College Hospital, Beijing Tiantan Hospital, Xuanwu Hospital, Beijing, Peking University Third Hospital, Beijing Hospital, Peking University First Hospital, Chinese PLA General Hospital
Primary Central Nervous System Lymphoma
08/22
08/24
NCT03064867: Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Active, not recruiting
1/2
65
US
Venetoclax, Rituximab, Rituxan, Ifosfamide, Ifex, Carboplatin, Paraplatin, Etoposide, VP-16, VePesid
Molly Gallogly
Diffuse Large B-cell-lymphoma
08/22
08/23
ChiCTR2200055163: A Phase Ib Study of TQ-B3525，a PI3K-α and -δ inhibitor, in Combination with Rituximab and Bendamustine in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Recruiting
1/2
30
 
TQ-B3525 in combination with rituximab and bendamustine
Sichuan Cancer Hospital; Sichuan Cancer Hospital, CHIATAI TIANQING
Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
 
 
PARADIGME, NCT01796171 / 2011-000033-36: A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma

Hourglass Jul 2018 - Dec 2018 : Completion of enrollment in pivotal P2 PARADIGME trial
Checkmark LYMRIT 37-01 data for r/r indolent NHL at ASH 2018
Nov 2018 - Nov 2018: LYMRIT 37-01 data for r/r indolent NHL at ASH 2018
Hourglass Oct 2016 - Dec 2016 : Dose escalation in arm 1 and either arm 3 or 4 of P1/2 Lymrit 37-01 trial for FL
Hourglass Oct 2016 - Dec 2016 : SRC review of data from arms 3 and 4 of P1/2 Lymrit 37-01 trial for FL
More
Completed
1/2
191
Europe, Canada, US, RoW
10 MBq/kg Betalutin, 15 MBq/kg Betalutin, 20 MBq/kg Betalutin, 40 mg lilotomab, 100 mg/m2 lilotomab, 60 mg/m2 lilotomab, Rituximab, 12.5 mBq/kg Betalutin
Nordic Nanovector, ICON Clinical Research
Non-Hodgkin Lymphoma, Follicular Lymphoma
10/22
10/22
VALERIA, NCT03505944 / 2017-001060-38: Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma

Active, not recruiting
1/2
59
Europe
Venetoclax
Nordic Lymphoma Group
Relapsed Non Hodgkin Lymphoma
12/22
12/22
NCT04507477: Ex-vivo Delivery of Rituximab to Prevent PTLD in EBV Mismatch Lung Transplant Recipients: A Pilot Trial

Recruiting
1/2
10
Canada
Rituximab, Rituxan
University Health Network, Toronto
Epstein-Barr Virus Infections, Post-transplant Lymphoproliferative Disorder
12/22
02/23
Epi-RCHOP, NCT02889523 / 2016-001499-31: Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy

Calendar Jan 2023 - Dec 2024: Data from P1b/2 trial for DLBCL and follicular lymphoma
Checkmark Initial combination data
Dec 2018 - Dec 2018: Initial combination data
Not Appicable May 2018 - May 2018 : Epi-RCHOP trial in 1L DLBCL [Trial suspended]
Checkmark Transition into P2 in P1/2 Epi-RCHOP trial in frontline DLBCL
More
Active, not recruiting
1/2
214
Europe
Tazemetostat, EPZ-6438, Rituximab, Mabthera, Cyclophosphamide, Vincristine, Doxorubicin, Prednisolone
The Lymphoma Academic Research Organisation, Epizyme, Inc.
Lymphoma, DLBCL, Follicular Lymphoma
01/23
04/26
NCT04464798: A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas

Active, not recruiting
1/2
62
Europe, US, RoW
CC-220, Iberdomide, Rituximab, Obinutuzumab
Celgene
Lymphoma
03/23
01/25
TAK-981-1501, NCT04074330: A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma

Terminated
1/2
38
Europe, Canada, Japan, US, RoW
TAK-981, Rituximab
Takeda
Lymphoma, Non-Hodgkin
04/23
04/23
2020-003946-36: Phase 1/2 Study of TAK-981 in Combination With Rituximab in Patients With Lymphoma

Not yet recruiting
1/2
180
Europe
NA, Rituximab, TAK-981, Concentrate for solution for infusion, MabThera
Takeda Development Center Americas, Inc., TAKEDA DEVELOPMENT CENTER AMERICAS INC., Takeda Development Center Americas, Inc. (TDC Americas)
Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma, Lymphoma, Diseases [C] - Cancer [C04]
 
 
NCI-2012-02072, NCT01664910: CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies

Completed
1/2
27
US
Allogeneic Bone Marrow Transplantation, Allo BMT, Allogeneic BMT, Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic Hematopoietic Cell Transplantation, Allogeneic Stem Cell Transplantation, HSC, HSCT, Anti-Thymocyte Globulin, Antithymocyte Globulin, Antithymocyte Serum, ATG, ATGAM, ATS, Thymoglobulin, Bendamustine Hydrochloride, Bendamustin Hydrochloride, Cytostasan Hydrochloride, Levact, Ribomustin, SyB L-0501, Treanda, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, Inotuzumab Ozogamicin, Besponsa, CMC-544, Way 207294, WAY-207294, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, PBSCT, Peripheral Blood Progenitor Cell Transplantation, Peripheral Stem Cell Support, Peripheral Stem Cell Transplant, Peripheral Stem Cell Transplantation, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, RTXM83, Tacrolimus, FK 506, Fujimycin, Hecoria, Prograf, Protopic
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Hematopoietic and Lymphoid Cell Neoplasm
06/23
06/23
NCT02213913: Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas

Active, not recruiting
1/2
46
US
lenalidomide, CC-5013, IMiD-1, Revlimid, etoposide, EPEG, VP-16, VP-16-213, prednisone, DeCortin, Deltra, vincristine sulfate, leurocristine sulfate, VCR, Vincasar PFS, doxorubicin hydrochloride, ADM, ADR, Adria, Adriamycin PFS, Adriamycin RDF, cyclophosphamide, CPM, CTX, Cytoxan, Endoxan, Endoxana, rituximab, IDEC-C2B8, IDEC-C2B8 monoclonal antibody, Mabthera, MOAB IDEC-C2B8, Rituxan, quality-of-life assessment, quality of life assessment, laboratory biomarker analysis
University of Chicago, National Cancer Institute (NCI)
Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Grade 3 Follicular Lymphoma, Contiguous Stage II Mantle Cell Lymphoma, Contiguous Stage II Marginal Zone Lymphoma, Contiguous Stage II Small Lymphocytic Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Progressive Hairy Cell Leukemia, Initial Treatment, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage 0 Chronic Lymphocytic Leukemia, Stage I Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Mixed Cell Lymphoma, Stage I Adult Diffuse Small Cleaved Cell Lymphoma, Stage I Adult Hodgkin Lymphoma, Stage I Adult Immunoblastic Large Cell Lymphoma, Stage I Chronic Lymphocytic Leukemia, Stage I Grade 1 Follicular Lymphoma, Stage I Grade 2 Follicular Lymphoma, Stage I Grade 3 Follicular Lymphoma, Stage I Mantle Cell Lymphoma, Stage I Marginal Zone Lymphoma, Stage I Small Lymphocytic Lymphoma, Stage II Adult Hodgkin Lymphoma, Stage II Chronic Lymphocytic Leukemia, Stage II Small Lymphocytic Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Small Lymphocytic Lymphoma, Testicular Lymphoma, Untreated Hairy Cell Leukemia, Waldenström Macroglobulinemia
07/23
07/23
NCT04421560: Pembrolizumab, Ibrutinib and Rituximab in PCNSL

Recruiting
1/2
37
US
Ibrutinib, Imbruvica, Pembrolizumab, Keytruda, Rituximab, Rituxan, Truxima
Dana-Farber Cancer Institute, Merck Sharp & Dohme LLC
Primary Central Nervous System Lymphoma, Recurrent Cancer, Refractory Cancer, Relapsed Cancer
08/24
03/25
NCT01484093: Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma

Completed
1/2
96
US
R-CHOP-14R-HIDAC,followed by RIT/HDT/ASCR., HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL RESCUE (ASCR)Patients admitted to the hospital for high dose chemotherapy. The anticipated length of, stay is 3-4 weeks. 14 days ± 1 day following the administration of the therapeutic dose of Iodine 131 I, Tositumomab, patients will be admitted for high-dose chemotherapy. BEAM, will be administered
Memorial Sloan Kettering Cancer Center, GlaxoSmithKline
Mantle Cell Lymphoma
08/23
08/23
NCT02632396: Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission

Active, not recruiting
1/2
12
US
Ixazomib, Ninlaro, MLN9708, Ixazomib Citrate, Rituximab, Rituxan, MabThera, Chimeric Anti-CD20 Antibody
Emory University, Millennium Pharmaceuticals, Inc., National Cancer Institute (NCI), National Institutes of Health (NIH)
Mantle Cell Lymphoma
08/23
08/24
ACE-LY-003, NCT02180711: Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma

Calendar Jan 2024 - Dec 2024: From trial for r/r follicular lymphoma
Hourglass Jul 2023 - Sep 2023 : Last patient dosing of P1 ACE-LY-003 trial for relapsed/refractory follicular lymphoma
Active, not recruiting
1/2
113
Europe, Canada, US
acalabrutinib, ACP-196, rituximab (IV), Lenalidomide
Acerta Pharma BV, AstraZeneca
Non Hodgkin Lymphoma
08/23
12/28
NCT02957019 / 2014-001949-25: A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Terminated
1/2
6
Europe
L19-IL2 - Ph I, L19-IL2 at RD - Ph II, Rituximab
Philogen S.p.A.
Diffuse Large B-cell Lymphoma (DLBCL)
09/23
09/23
GO40515, NCT03677141 / 2018-001039-29: A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma

Checkmark Data from trial in combination with CHOP for 1L DLBCL at ASH 2020
Dec 2020 - Dec 2020: Data from trial in combination with CHOP for 1L DLBCL at ASH 2020
Completed
1/2
117
Europe, US, RoW
Mosunetuzumab, Polatuzumab Vedotin, Rituxumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tocilizumab
Hoffmann-La Roche
B-cell Non-Hodgkin Lymphoma
10/23
10/23
NCT03500731: Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure

Recruiting
1/2
8
US
CD3/CD19 negative hematopoietic stem cells, Rituximab, Rituxan, Alemtuzumab, Campath-1H, Fludarabine, Fludara, Oforta, Thiotepa, G-CSF, Neupogen, Granix, Zarxio, Filgrastim, Hydroxyurea
Paul Szabolcs
Idiopathic Pulmonary Fibrosis, Emphysema or COPD
12/24
12/26
TREND, NCT04058470: Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma

Recruiting
1/2
140
RoW
Toripalimab, Rituximab, JS001, Rituximab, R-CHOP Protocol, Rituximab,Cyclophosphamide,Doxorubicin,Vincristine,Prednisone
Huiqiang Huang
Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Grade IIIb, Transformed Lymphoma, EBV-Positive DLBCL, Nos, ALK-Positive Anaplastic Large Cell Lymphoma
12/23
12/25
NCT04856137: A Phase I/II Study of Diffuse Large B-cell Lymphoma

Not yet recruiting
1/2
74
NA
Rituximab Paclitaxel Ruxolitinib, G-CSF 1PC sc qd
National Health Research Institutes, Taiwan, Taipei Veterans General Hospital, Taiwan, Chang Gung Memorial Hospital, China Medical University Hospital, Shin Kong Wu Huo-Shih Memorial Hospital
Refractory Diffuse Large B-cell Lymphoma
12/23
12/28
NCT02356159: Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Recruiting
1/2
50
US
Rituximab, Conditioning chemotherapy, TMS, FLAG, EPOCH-F, Hematopoietic stem cell transplant, Palifermin
National Cancer Institute (NCI)
Myelodysplastic Syndrome, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Acute Leukemia, Multiple Myeloma
12/24
12/24
COALITION, NCT04914741: A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)

Active, not recruiting
1/2
80
RoW
Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, Glofitamab, RO7082859, CD20-TCB, Polatuzumab vedotin
Peter MacCallum Cancer Centre, Australia, Hoffmann-La Roche
Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
01/24
07/25
R-MPV, NCT04446962: LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin

Recruiting
1/2
118
Europe
Lenalidomide, Revlimid, Ibrutinib, Imbruvica
Institut Curie, National Cancer Institute, France
Lymphoma, Large B-Cell, Diffuse, Central Nervous System Neoplasms, Primary
01/24
01/31
NCT05577364: Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients

Recruiting
1/2
54
RoW
Selinexor, exportin 1 (XPO1) inhibitor, R-CHOP Protocol, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
Sun Yat-sen University, Fudan University, Antengene Corporation
EBV-Positive Diffuse Large B-Cell Lymphoma, Nos
12/24
02/26
BRUIN, NCT03740529 / 2018-003340-24: A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

Active, not recruiting
1/2
860
Europe, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, B-cell Lymphoma, Small Lymphocytic Lymphoma
09/27
01/28
NCT03492125: A Study Of The Selective PKC-β Inhibitor MS- 553

Recruiting
1/2
117
US
MS-553, acalabrutinib, venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, obinutuzumab, Gazyva
MingSight Pharmaceuticals, Inc
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Aggressive Lymphoma
04/24
06/24
 

Download Options